Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Australian Clinical Labs Limited has announced that it will release its financial results for the year ending June 30, 2025, on August 26, 2025. The company’s Annual General Meeting is scheduled for October 23, 2025, with details to be shared with shareholders. This announcement outlines the procedural requirements for shareholders wishing to nominate candidates for the board, emphasizing the company’s commitment to governance and stakeholder engagement.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.60 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs (ACL) is a leading private provider of pathology services in Australia. The company operates NATA accredited laboratories that conduct a wide range of pathology tests for doctors, specialists, patients, hospitals, and corporate clients. ACL is one of the largest private hospital pathology businesses in the country, focusing on combining skilled personnel, medical and scientific leadership, and innovative technologies to enhance decision-making and improve patient outcomes.
Average Trading Volume: 830,904
Technical Sentiment Signal: Sell
Current Market Cap: A$532.2M
For an in-depth examination of ACL stock, go to TipRanks’ Overview page.